Alzheimer Disease Diagnostics Market Will Grow Rapidly In Coming Years

 The global Alzheimer’s disease diagnostics market is moving toward earlier, more precise, and less invasive detection as healthcare systems respond to the growing burden of Alzheimer’s disease and an aging population. According to Grand View Research, the market was valued at USD 9.2 billion in 2025 and is estimated to reach USD 10.2 billion in 2026. It is projected to reach USD 21.5 billion by 2033, expanding at a CAGR of 11.2% from 2026 to 2033. North America held the largest regional share at 47.5% in 2025, while Asia Pacific is expected to be the fastest-growing region.

AI is becoming an important supporting technology for Alzheimer’s diagnostics. AI-enabled imaging software can analyze MRI and other neurological images, while machine learning can help interpret biomarkers, genetic information, and clinical data. Recent research is also moving toward multimodal AI that combines imaging, blood biomarkers, cognitive assessments, and longitudinal patient information. This creates opportunities for more personalized and earlier diagnosis, although clinical validation, data quality, privacy, and explainability remain important considerations.

Track Market Growth and Metrics

The Alzheimer’s disease diagnostics market is expected to experience strong expansion throughout the forecast period. Grand View Research estimates growth from USD 10.2 billion in 2026 to USD 21.5 billion by 2033 at an 11.2% CAGR. The market is being supported by the rising prevalence of Alzheimer’s disease, growing use of biomarkers, personalized healthcare approaches, government investment, research activity, and improvements in medical imaging.

The aging population is a major structural factor behind market growth. As the number of older adults increases, healthcare providers require diagnostic technologies that can identify Alzheimer’s pathology earlier and distinguish it from other causes of cognitive decline. The increasing development of disease-modifying treatments is also strengthening demand for diagnostic tools capable of identifying amyloid pathology and helping determine appropriate patient populations.

Download a free sample copy of the Alzheimer Disease Diagnostics market report to understand detailed coverage and inclusions in the final report

Global Revenue Forecast

Global revenue is expected to more than double between 2026 and 2033. The market is forecast to increase from USD 10.2 billion in 2026 to USD 21.5 billion by 2033, reflecting sustained demand for advanced diagnostic technologies. Imaging remains commercially important, while biomarkers are expected to record the fastest growth during the forecast period.

Blood-based testing represents one of the most important opportunities within this expansion. Traditional approaches such as cerebrospinal fluid analysis and amyloid PET can be costly or invasive. Blood biomarkers may offer a more convenient approach for identifying Alzheimer’s-related pathology and supporting clinical workflows. In May 2025, the FDA approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio as the first in vitro diagnostic equipment designed for blood analysis to assist in diagnosing Alzheimer’s disease in appropriate symptomatic adults.

Regional Hub Performance

North America remained the leading regional market, accounting for 47.5% of global revenue in 2025. The region benefits from advanced healthcare infrastructure, strong research capabilities, major diagnostic companies, and extensive development of Alzheimer’s biomarkers. The U.S. held the largest country-level market share in 2025.

Asia Pacific is expected to be the fastest-growing region from 2026 to 2033. Increasing diagnostic research, expanding healthcare infrastructure, growing investment in medical technologies, and the rising need to manage neurological diseases are creating opportunities across countries including China, Japan, India, Australia, and South Korea.

Pinpoint Key Market Drivers

The increasing prevalence of Alzheimer’s disease is one of the strongest market drivers. Population aging is increasing the number of people at risk, creating greater demand for reliable diagnostic tools. Government investments and research programs are also supporting innovation in biomarkers, imaging, genetic testing, and cognitive assessment technologies.

Another major driver is the increasing importance of biomarkers. Advances in genomics, proteomics, and metabolomics are expanding the range of biological signals that can be used to support diagnosis. Amyloid-beta and tau biomarkers are particularly important because they provide information about disease-related pathology.

Analyze Segment Metrics

• By diagnostics technique, imaging techniques held the largest share at 40.8% in 2025. CT, PET, and functional MRI technologies are used to identify structural and molecular changes associated with Alzheimer’s disease. AI is also strengthening imaging capabilities. For example, Pixyl received FDA 510(k) clearance for its AI-powered Pixyl.Neuro brain MRI software, designed to support faster detection and objective monitoring of neurological disorders.
• The biomarkers segment is expected to be the fastest-growing technique segment. It includes CSF biomarkers and blood-based biomarkers. Blood-based tests are attracting particular attention because they can potentially provide a less invasive alternative to conventional diagnostic approaches.
• By type, the diagnosis segment accounted for 54.1% of revenue in 2025, reflecting the increasing need for accurate confirmation of Alzheimer’s pathology. By end use, academic and research institutes held 48.3% of the market, supported by clinical trials, neurological research, and the development of innovative diagnostic methods.

Looking for more specific insights? Customize this report to suite your business needs

Identify Major Industry Players

The competitive landscape includes major diagnostic, biotechnology, imaging, and healthcare technology companies. Grand View Research identifies Quest Diagnostics, Labcorp, C2N Diagnostics, Fujirebio, Hoffmann-La Roche, Quanterix, Sysmex, Lantheus, and Siemens Healthineers among the key companies profiled in the market.

Companies are competing through biomarker development, imaging solutions, laboratory automation, strategic partnerships, acquisitions, and clinical validation. Lantheus has expanded its Alzheimer’s imaging capabilities through acquisitions, while C2N Diagnostics launched PrecivityAD2 blood tests in 2025. These developments demonstrate the industry's shift toward accessible biomarker-based diagnostics.

Spot Emerging 2026 Trends

In 2026, the strongest trend is the movement from invasive and expensive diagnostic procedures toward blood-based biomarker testing. Another important trend is the integration of AI with imaging and biomarker data to support faster and more consistent interpretation. Multimodal diagnostic platforms that combine blood biomarkers, PET or MRI imaging, cognitive assessments, genetics, and digital health data are also gaining research attention.

The market is also moving toward earlier diagnosis because emerging disease-modifying therapies increase the importance of identifying appropriate patients before substantial disease progression. At the same time, regulatory clearance and clinical validation are becoming critical competitive factors as diagnostic companies move new technologies from research environments into routine healthcare.

Explore our dedicated business services:

• US Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.